$4.55
4.36%
NYSE, Jan 02, 10:04 pm CET
ISIN
US36870H1032
Symbol
GNLX

Genelux Stock price

$4.55
-0.18 3.81% 1M
+1.71 60.21% 6M
+0.19 4.36% YTD
+2.14 88.80% 1Y
-1.45 24.17% 3Y
-1.45 24.17% 5Y
-1.45 24.17% 10Y
-1.45 24.17% 20Y
NYSE, Closing price Fri, Jan 02 2026
+0.19 4.36%
ISIN
US36870H1032
Symbol
GNLX
Industry

Key metrics

Basic
Market capitalization
$173.1m
Enterprise Value
$152.2m
Net debt
positive
Cash
$20.9m
Shares outstanding
37.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
9.3
Financial Health
Equity Ratio
75.7%
Return on Equity
-113.7%
ROCE
-167.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-32.9m | $-21.9m
EBIT
$-33.2m | $-33.1m
Net Income
$-31.9m | $-32.5m
Free Cash Flow
$-24.1m
Growth (TTM | estimate)
Revenue
-100.0% | -100.0%
EBITDA
-14.9% | 30.3%
EBIT
-14.6% | -4.4%
Net Income
-15.2% | -8.9%
Free Cash Flow
1.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.8
FCF per Share
$-0.6
Short interest
8.3%
Employees
24
Rev per Employee
$0.0
Show more

Is Genelux a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Genelux Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Genelux forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Genelux forecast:

Buy
92%
Hold
8%

Financial data from Genelux

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
4% 4%
-
- Research and Development Expense 21 21
-
-
-33 -33
15% 15%
-
- Depreciation and Amortization 0.24 0.24
14% 14%
-
EBIT (Operating Income) EBIT -33 -33
15% 15%
-
Net Profit -32 -32
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Genelux directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genelux Stock News

Neutral
GlobeNewsWire
one day ago
WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones.
Neutral
GlobeNewsWire
about 2 months ago
-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 --
Neutral
GlobeNewsWire
5 months ago
WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates.
More Genelux News

Company Profile

Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.

Head office United States
CEO Thomas Zindrick
Employees 24
Founded 2001
Website genelux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today